SEC Form 4 · accession 0001209191-18-035083
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Arkowitz
Officer — Chief Financial Officer
Period of report
Jun 1, 2018
Accepted (ET)
Jun 4, 2018 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2018 | A | 30,000 | $0.00 | A | 40,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $27.01 | Jun 1, 2018 | A | 115,000 | A | — | May 31, 2028 | Common Stock | 115,000 | 115,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest one year after May 7, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of May 7, 2018, so that all of the shares subject to the option shall be vested four (4) years after May 7, 2018.